Singer Avery warns Ozempic gave her a debilitating disease
By isabelle // 2025-02-03
Copy
 
  • Singer Avery reveals on Instagram that Ozempic, a popular weight-loss drug, has caused her to develop osteoporosis.
  • Avery’s journey with Ozempic began after being dropped by her label for being "too fat," leading her to misuse the drug for rapid weight loss.
  • Medical research links Ozempic to severe side effects, including significant bone density loss and gastroparesis.
  • Avery warns her 250,000 followers against using the drug if not medically necessary and calls for greater regulation of such medications.
  • Her story highlights the risks of the pharmaceutical industry's focus on quick-fix solutions and the need for a more holistic approach to health.
In a heartfelt and tearful video posted to Instagram, singer Avery, a 30-year-old from Phoenix, Arizona, revealed her harrowing experience with the weight-loss drug Ozempic, which she claims has left her with osteoporosis, a debilitating bone-thinning disease. Avery, known for her single "Let Me Go," shared her story to warn her 250,000 followers about the potential dangers of the drug, which has gained widespread popularity for its rapid weight-loss effects. Avery’s journey with Ozempic began after she was dropped by her record label for being "too fat." Struggling with an eating disorder, she turned to the drug, believing it was her ticket to beauty and success. However, just a year later, she found herself facing a life-altering diagnosis. "I'm kind of in shock right now because I wasn't expecting this," Avery said in the video. "Ozempic can cause bone density loss, and I didn't think that would happen to me because I was only on it for a year. But I have significant bone loss, I have osteoporosis and osteopenia."

The dark side of Ozempic

Ozempic, a drug primarily designed to help type 2 diabetes patients and obese individuals control their blood sugar levels and lose weight, has become a sensation in the weight-loss industry. However, the drug's side effects are raising serious concerns among medical professionals and patients alike. Avery’s case is not isolated; research has linked Ozempic to a range of negative health outcomes, including severe gastrointestinal issues, fatigue, and, most alarmingly, gastroparesis, a condition often referred to as "stomach paralysis." Gastroparesis, a condition where the stomach muscles stop functioning properly, can lead to severe nausea, vomiting, and persistent bloating. Dr. Prateek Sharma, a professor of medicine at the University of Kansas School of Medicine, presented research at Digestive Disease Week 2024, which found that patients taking GLP-1 drugs like Ozempic were 66% more likely to be diagnosed with gastroparesis compared to those who did not take the medication. Despite the name, gastroparesis does not cause actual paralysis of the stomach but can significantly impair a person's quality of life.

Big Pharma’s profit-driven model

Avery’s story is a reminder of the risks associated with the pharmaceutical industry's push for quick-fix solutions. Big Pharma's focus on providing rapid results often overshadows the long-term health consequences of their products. The ease with which Ozempic can be obtained, even by those without a legitimate medical need, has led to a surge in misuse and overprescription. This business model, where patients are encouraged to rely on medication for weight loss and other health issues, often leaves them with more problems than they started with, creating a cycle of dependency on additional medications to manage the side effects. The drug's origins also raise ethical questions. Ozempic is derived from the venom of the Gila monster, a venomous lizard native to the United States. While the drug's ability to mimic the effects of the lizard's venom has been celebrated by some for its effectiveness, the use of animal venom in pharmaceuticals underscores the lengths to which companies will go to create blockbuster drugs, often at the expense of patient safety. Avery’s plea to her followers is a call to action for the broader public and medical community. "Please don’t take this drug if you don’t need it. Please use me as an example," she urged. Her story highlights the need for greater regulation and oversight of medications like Ozempic, as well as a more holistic approach to health and wellness that emphasizes lifestyle changes over quick fixes. As more individuals come forward with similar stories, the conversation around the safety and efficacy of Ozempic and other GLP-1 drugs is likely to intensify. For now, Avery is focused on her recovery and hopes that her experience will prevent others from making the same mistake. "I will be going on medication and starting a treatment plan. I will know more soon. It is not always reversible, but I can do things to improve the situation," she said, adding, "At the moment I have to be very careful, as my bones are brittle. But it is treatable, and I will be okay. Thank you for your support." Sources for this article include: X.com DailyMail.co.uk FoxNews.com DailyMail.co.uk Healthline.com
Copy